Frequently asked questions

No. No blood biomarker test can tell you with certainty whether you will develop Alzheimer’s dementia or when it might occur. ALZInsights measures biomarkers associated with Alzheimer’s-related amyloid pathology and provides information about whether that biological pattern is likely to be present at the time of testing.

In clinical research involving the Beckman Coulter biomarker test, among patients receiving a clear result, 91.2% of positive results corresponded with amyloid positivity and 90.4% of negative results corresponded with amyloid negativity.

These figures describe the test’s ability to identify Alzheimer’s-associated amyloid pathology — not its ability to predict whether someone will eventually develop Alzheimer’s dementia.

No. A higher-likelihood biomarker result is not, by itself, a diagnosis of Alzheimer’s disease or Alzheimer’s dementia.

It indicates that the biological pattern measured by the test is associated with a higher likelihood of amyloid pathology.

You may choose to discuss a higher result with a neurologist, memory specialist or other healthcare professional.

No. A lower result indicates a lower likelihood of Alzheimer’s-associated amyloid pathology at the time you are tested.

It cannot guarantee that you will never develop Alzheimer’s disease in the future.


No. ALZInsights does not analyze your DNA or determine whether you carry a genetic variant associated with Alzheimer’s.

It measures proteins circulating in your blood that are associated with biological changes seen in Alzheimer’s disease.


No. ALZInsights is self-directed. No physician referral or doctor’s office visit is required to place your order.

If your result raises questions or you are experiencing changes in memory or thinking, you may choose to discuss your result with a healthcare professional.


There is currently no lifestyle change that can guarantee Alzheimer’s disease will be prevented.

However, physical activity, healthy eating, cardiovascular risk management, adequate sleep, social engagement and other healthy behaviors are associated with better brain health and may help reduce the risk of cognitive decline and dementia.

The earlier you adopt healthy behaviors, the longer you may benefit from them.

Knowing doesn’t determine your future.


It gives you more information to help you shape it.

You can’t control everything that may happen years from now. But information can give you choices.

Choices about your health.

Choices about your plans.

Choices about your family.

Choices about your priorities.

And choices about what you want to do with the time ahead.

A simple blood test can now provide insight into biological changes associated with Alzheimer’s disease that once required far more complicated testing to identify. You decide whether you want to know.

ALZInsights makes knowing more possible.


Order Your ALZInsights Test

Important Information

ALZInsights measures blood-based biomarkers associated with amyloid pathology seen in Alzheimer’s disease. The test does not independently diagnose Alzheimer’s disease or Alzheimer’s dementia and does not predict whether or when an individual will develop Alzheimer’s disease. Positive, negative and indeterminate results may occur. Results should be interpreted according to the FDA-approved intended use and labeling for the Beckman Coulter assay. Individuals experiencing changes in memory, thinking or behavior should consider discussing those symptoms with a qualified healthcare professional.

Lifestyle information provided by ALZInsights is for general educational purposes and is not intended as medical advice. Lifestyle changes cannot guarantee prevention or delay of Alzheimer’s disease.

ALZInsights does not provide legal, financial, insurance or retirement advice. Insurance eligibility, underwriting and disclosure requirements vary.